Biogen

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

tmcnet.com     16 hrs ago   14 related          

710M for Elotuzumab After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. The deal calls for New...                    

comments

                   

Stromedix's Allograft Nephropathy Drug STX-100 Gets Orphan Drug Status from US FDA

pharmiweb.co.uk     15 hrs ago          

Wednesday, August 20, 2008 -- -- Stromedix Inc, a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced that its lead clinical candidate STX-100 has been granted orphan drug...                    

comments

                   

Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain...

drugs.com     yesterday   4 related          

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Aug 19, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to...                    

comments

                   

National Geographic and NewsGator Partner to Create Viral Widget Campaign

digitalmediaonlineinc.com     yesterday   2 related          

DENVER , Aug. 19 /PRNewswire/ — NewsGator Technologies, Inc. today announced that it has partnered with National Geographic to create, host and track a series of dynamic widgets, including an interactive puzzle widget that...                    

comments

                   

Cascade Controls Changes Corporate Identity to Cascade Solutions

prnewswire.com     yesterday          

Company seeks to better emphasize its customer-centric business approach. Cascade Controls, Inc., a Chicago-area based process and automation engineering firm with offices in Boston and San Francisco, announced today that the...                    

comments

Cell Therapeutics running out of cash

nwsource.com     Aug 19, 2008   2 related          

Cell Therapeutics said Monday that it will need to raise money soon because its current available cash won't last beyond September. By Ángel González Seattle Times business reporter Cell Therapeutics said Monday it will need to...                    

comments

                   

Alnylam and Collaborators Publish New Preclinical Research on RNAi-Mediated Silencing of PCSK9

drugs.com     Aug 18, 2008   1 related          

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 12, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that new pre-clinical data from its hypercholesterolemia program was published...                    

comments

                   

Plan for anaerobic digesters in every town to recycle leftovers

timesonline.co.uk     Aug 19, 2008   4 related          

Lewis Smith, Environment Reporter Waste-disposal units designed to turn leftover food into electricity and fertiliser could be built around every town and city as part of a scheme being considered by ministers. Most waste food...                    

comments

Tysabri Forecast to Achieve Blockbuster Status by 2014

pharmiweb.co.uk     Aug 19, 2008          

AVOS Life Sciences Posted on:19 Aug 08 MORRISVILLE, N.C. (Aug. 18, 2008) - AVOS Life Sciences contends that Tysabri will exceed $1 billion in sales by 2014 as previously forecasted in the AVOS Therapeutic Market Outlook (TMO)...                    

comments

                   

Beacon Equity Issues Technical Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD

emailwire.com     Aug 18, 2008   8 related          

DALLAS, Texas - Today’s Trade Alerts include: Elan Corp. plc (NYSE: ELN), Pfizer Inc. (NYSE: PFE), Amgen Inc. (Nasdaq: AMGN), Genentech Inc. (NYSE: DNA), Biogen Idec Inc. (Nasdaq: BIIB), and Gilead Sciences Inc. (Nasdaq: GILD)....                    

comments

1 2 3 4 5 next »